Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2009

View Archived Issues

Karo Bio present update on drug development programs

Dienogest exhibits favorable safety profile in the long-term treatment of endometriosis

Phase I study results encourage further development of anesthetic PF-0713

EMEA committee informs Antigenics of negative opinion on MAA for Oncophage in RCC

Gilead reports results from third quarter of 2009

PSN-0041 displays enhanced antidepressant activity over native amylin in preclinical tests

Preclinical characterization of SEP-230864 presented by Sepracor

KB-099520 increases serotonergic activity and demonstrates antidepressant effects

IMO-3100 active in arthritis model, intended for clinical development

Naproxcinod efficacy similar to naproxen in knee osteoarthritis patients

Brain autoimmune mechanisms implicated in the pathogenesis of OCD / News in Context

Peregrine reports positive tumor response rate in phase II bavituximab trial

Aerie reports phase IIa results for ROCK inhibitor, AR-12286, in glaucoma

AcelRx presents results from phase II ARX-03 study

KemPharm commences phase I KP-106 trial in ADHD

Roche doses first patient in phase III subcutaneous Herceptin trial

TargeGen completes TG-101348 trial in patients with myelofibrosis

NexGenix awarded phase I grant for small-molecule Hsp90 compounds for glioma

Repligen licenses compounds for potential spinal muscular atrophy treatment

Merck and Schering-Plough receive European Commission clearance for merger

Aeolus drug protects gastrointestinal tract in acute radiation syndrome studies

CHMP recommends Boehringer's Micardis for CV morbidity in high CV risk patients

Onyx and Bayer initiate phase III trial of Nexavar in nonresponsive thyroid cancer

Pharmaxis commences pivotal bronchiectasis study with Bronchitol

CGRP antagonists for the treatment of migraine claimed by Merck & Co.

New glucokinase activators described by Astellas Pharma as antidiabetic agents

GlaxoSmithKline presents antiviral compounds for HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...